Abstract Although B cells expressing the IFNgR or the IFNg-inducible transcription factor T-bet promote autoimmunity in Systemic Lupus Erythematosus (SLE)-prone mouse models, the role for IFNg signaling in human antibody responses is unknown. We show that elevated levels of IFNg in SLE patients correlate with expansion of the T-bet expressing 
Introduction
Systemic Lupus Erythematosus (SLE) is characterized by progressive dysregulation of the innate and adaptive arms of the immune system, which ultimately leads to loss of immune tolerance in B and T lymphocytes and the production of autoantibodies (Abs) by Ab-secreting B cells (ASCs) . The hallmark SLE autoAbs recognize nuclear proteins and nucleic acids (Gatto et al., 2016) , which are also ligands for TLR7 and TLR9 that are expressed by innate immune cells and B cells (Avalos et al., 2010) . SLE autoAbs bound to their autoAgs form immune complexes, which are responsible for many of the clinical manifestations of SLE, particularly those associated with organ damage (Gatto et al., 2016) . Consistent with the important role for B cells and ASCs in SLE pathogenesis (Sanz, 2014) , the only new drug approved to treat SLE in decades, Belimumab, targets B cells.
Inflammatory cytokines and chemokines also contribute to SLE pathogenesis (Apostolidis et al., 2011) . SLE patient PBMCs often exhibit a type I interferon (IFN) transcriptional signature and systemic IFNa is elevated in many patients (Obermoser and Pascual, 2010) . It is less well appreciated that IFNg is also increased in some SLE patients (Csiszár et al., 2000; Harigai et al., 2008; Pollard et al., 2013) and that a distinct IFNg transcription signature can be detected in PBMCs from a portion of SLE patients (Chiche et al., 2014; Welcher et al., 2015) . Interestingly, elevated serum IFNg can be observed years before IFNa or autoAbs are detected in SLE patients and much earlier than clinical disease Lu et al., 2016) . Consistent with these observations, B cells from SLE patients can exhibit signs of prior IFNg exposure. For example, two IFNg-inducible proteins, CXCR3 and T-bet, are more highly expressed by circulating B cells from SLE patients compared to healthy controls (Harigai et al., 2008; Nicholas et al., 2008; Lit et al., 2007; Wang et al., 2018; Jenks et al., 2018) . Moreover, data from mouse SLE models show that clinical disease is dependent on B cell-specific expression of the IFNgR and the IFNg-induced transcription factors (TF) STAT1 (Domeier et al., 2016; Jackson et al., 2016; Thibault et al., 2008) and T-bet in some Liu et al., 2017) but not all (Jackson et al., 2016; Du et al., 2019 ) models. Taken together, these data suggest that IFNg-driven inflammation may contribute to SLE B celldriven pathophysiology.
Two interrelated populations of circulating B cells present in SLE patients, namely the CD11c hi B cells, which are also called age associated B cells (ABCs) (Karnell et al., 2017; , and the IgD neg CD27 neg B double negative (B DN ) B cells, which are often referred to as 'atypical' memory B cells (Wei et al., 2007; Portugal et al., 2017) , are reported to express the IFNginducible TF T-bet. These B cells, which may have been exposed to IFNg at some step in their developmental process, are present in low numbers in the blood or tonsils of healthy individuals (Ehrhardt et al., 2005) and are reported to be expanded in chronically infected, aging and autoimmune individuals (reviewed in Naradikian et al., 2016) , including patients with SLE Jenks et al., 2018) . The CD11c hi population found in SLE patients is heterogeneous and con- . The B DN population is also heterogeneous and can be subdivided using CD11c and CXCR5 into the DN2 (CD11c hi CXCR5 neg ) subset, which express T-bet, and the DN1 (CD11c lo CXCR5 + ) subset, which does not express T-bet (Jenks et al., 2018) .
Despite extensive data showing that these overlapping populations of CD11c hi B cells and B DN cells are expanded in a number of human diseases (Naradikian et al., 2016) , our understanding regarding their origin and function is incomplete. Although initial studies examining B DN cells from malaria or HIV-infected individuals described these B cells as anergic (reviewed in Portugal et al., 2017) , more recent studies reported that the CD11c-expressing IgD neg CD27 + CD21 lo activated B SW cells from influenza vaccinated humans (Lau et al., 2017) and HIV infected patients (Knox et al., 2017) , as well as the CD11c hi cells from SLE patients ) and the CD11c hi DN2 cells from SLE patients (Jenks et al., 2018) possess phenotypic and molecular characteristics of preASCs. Both the CD11c hi B cells and the more narrowly defined DN2 subset from SLE patients differentiate into ASCs following stimulation Jenks et al., 2018) . Moreover, the T-bet hi DN2 subset from SLE patients can produce autoAbs (Jenks et al., 2018) , suggesting that these cells can potentially contribute to disease. Since T-bet hi DN2 pre-ASCs produce autoAbs and correlate with disease severity in SLE patients (Jenks et al., 2018) , we set out to identify the signals that control the development and differentiation of this population into ASCs. Here we show that expansion of the DN2 cells in SLE patients correlates with systemic concentrations of IFNg and IFNg-induced cytokines. We demonstrate that activation of naïve B (B N ) cells from healthy donors or SLE patients with IFNg-producing T cells or IFNg+TLR7/8 and BCR ligands induces formation of a T-bet hi pre-ASC population that is phenotypically, transcriptionally and functionally similar to the SLE T-bet hi DN2 subset. We show that IFNg signals significantly augment ASC differentiation by sensitizing B N cells to respond to BCR, IL-2 and TLR7/8 signals and by promoting global epigenetic changes in the activated B cells that lead to significantly increased chromatin accessibility surrounding binding sites for the key ASC commitment TFs, BLIMP1 and IRF4. We find IFNg-dependent differentially accessible regions (DARs) within the IL21R and PRDM1 (BLIMP1) loci and show that early IFNg signaling promotes increased IL-21R expression and responsiveness. Finally, we observe that the key IFNg-regulated epigenetic changes in the in vitro generated T-bet hi B DN pre-ASC subset and the molecular signals required to induce ASC development are conserved in the SLE patient DN2 cells. Collectively, these data suggest that IFNg signals can augment ASC development and may regulate the formation of pathogenic autoreactive pre-ASCs in some SLE patients.
Results

Expansion of T-bet hi DN2 cells correlates with systemic IFNg levels in SLE patients
Recent studies from our group (Stone et al., 2019) revealed that differentiation of mouse B cells activated in the presence of IFNg-producing T cells was dependent on B cell intrinsic expression of the IFNgR and the IFNg-induced transcription factor (TF), T-bet. This result fit well with data from our group (Figure 1-figure supplement 1) and others Liu et al., 2017) showing that B cell intrinsic expression of T-bet is required for the development of autoAb-mediated disease in SLE mouse models and suggested that IFNg signaling in B cells might also regulate development of ASCs from autoreactive B cells. Consistent with this possibility, we and others Jenks et al., 2018 ) identified a population of circulating T-bet-expressing B cells in SLE patients, referred to as DN2 cells (Jenks et al., 2018) , that express high levels of T-bet and exhibit phenotypic and functional properties of pre-ASCs. Based on these data, we postulated that the T-bet hi DN2 pre-ASC population that is expanded in a subset of SLE patients likely arises in response to IFNg-dependent signals. To test this hypothesis, we first assessed whether expansion of the T-bet hi DN2 pre-ASC subset in SLE patients correlated with IFNg levels in these patients. Consistent with our prior studies using a different cohort of SLE patients (Jenks et al., 2018) , we observed that a subset of our SLE patients presented with an expanded population of circulating IgD neg CD27-neg (double negative, B DN cells) (Figure 1a (Figure 1g ). Next, we measured cytokines in plasma from the SLE patients (Figure 1h -k). Consistent with our hypothesis, we observed a significant positive correlation between IFNg, as well as the IFNg-induced cytokines CXCL10, IL-6 and TNFa, and the frequency of T-bet hi DN2 cells in these individuals (Figure 1h ). These data therefore indicated that the circulating T-bet hi B DN cells present in our SLE patient cohort were phenotypically identical to the previously described (Jenks et al., 2018 ) DN2 pre-ASC subset and that this pre-ASC population is most expanded in SLE patients with elevated amounts of autoAbs, IFNg and IFNg-driven inflammatory cytokines.
IFNg-producing Th1 cells promote development of T-bet hi B DN cells and ASCs
Since IFNg can induce T-bet expression in B cells (Stone et al., 2019 ) and the T-bet hi DN2 pre-ASCs are expanded in SLE patients with higher systemic levels of IFNg, we predicted that the IFNg might regulate the formation of T-bet hi pre-ASCs. To test this, we developed an in vitro B cell/T cell mixed lymphocyte reaction (MLR) paired co-culture system ( Figure 2a) containing B N cells (purified as described in Figure 2 -figure supplement 1a) purified from the peripheral blood or tonsil of one HD and highly polarized human Th1 and Th2 effectors (Zhu et al., 2010) , which were generated in vitro using purified naïve peripheral blood T cells isolated from a second unrelated HD. The Th1 cells expressed T-bet and produced IFNg and IL-8 following restimulation while Th2 cells expressed GATA-3 and produced elevated levels of IL-4, IL-5, and IL-13 (Figure 2-figure supplement 1b-c). Since neither the Th1 nor Th2 cells produced IL-21 following restimulation (Figure 2 -figure supplement 1d), we added IL-21 to the co-cultures to ensure optimal B N activation (Ettinger et al., 2008; Tangye, 2015) and included IL-2 to enhance the survival of the T effectors (Rochman et al., 2009 In addition to observing the T-bet hi B DN pre-ASC like population in the Be1 co-cultures, we also identified CD38 hi CD27 + ASCs in both the Be1 and Be2 co-cultures ( Figure 2d ). However, we always found more ASCs in the Be1 co-cultures, even across multiple experiments using B N and T effectors from different HD pairs ( Figure 2e ). To address whether the increased ASC formation observed in the Be1 co-cultures was limited to isotype switched or unswitched B cells, we measured the frequency of IgM and IgG-producing (gated as in Figure 2 -figure supplement 2) ASCs across multiple paired Be1 and Be2 co-cultures. Again, we found that ASCs, regardless of isotype, were greatly enriched in the Be1 co-cultures (Figure 2f-g ). This increase in ASCs in the Be1 co-cultures was not due to intrinsic differences in the proliferative rates of the cells in each culture but rather that a higher proportion of the Be1 cells at each cell division committed to the ASC lineage ( 
T-bet hi B DN cells induced with Th1 cells and IL-21 are pre-ASCs
Given the phenotypic similarities between the in vitro generated T-bet hi B DN cells and SLE patient T-bet hi DN2 cells and the fact that the in vitro cultures containing T-bet hi B DN cells also efficiently formed ASCs, we predicted that the in vitro generated Tbet hi B DN cells were likely to be pre-ASCs.
To test this, we first asked whether the in vitro generated T-bet hi B DN cells were transcriptionally related to SLE patient-derived T-bet hi DN2 pre-ASCs or to ASCs from HD. We therefore sort-purified IgD neg CD27 neg B DN cells ( Figure 3a ) from 3 independent paired day 6 Be1 and Be2 co-cultures and performed RNA-seq analysis (Supplementary file 1). We identified 427 differentially expressed genes (DEGs) between the B DN cells from the Be1 and Be2 co-cultures ( Figure 3b ). Consistent with our data showing that T-bet was selectively upregulated in the B cells from Be1 co-cultures, we observed significantly higher levels of TBX21 mRNA in the in vitro induced B DN Be1 cells compared to B DN Be2 cells ( Figure 3c ). Next, we used Gene Set Enrichment Analysis (GSEA) to compare the transcriptomes of the in vitro generated Be1 and Be2 B DN cells to the T-bet hi DN2 population isolated from SLE patients (Jenks et al., 2018 , Supplementary file 2) and to curated ASC transcriptome datasets (Abbas et al., 2005; Tarte et al., 2003) . Consistent with our phenotyping data, the transcriptome of the T-bet expressing B DN Be1 cell subset was highly enriched relative to the B DN Be2 cells for genes that are specifically upregulated in the SLE-derived T-bet hi DN2 subset ( Figure 3d) . Moreover, the transcriptome of the in vitro-induced B DN Be1 population was significantly enriched in expression of genes that are upregulated in ASCs compared to B N cells (Figure 3e ), mature B cells ( Figure 3f ) and switched memory B cells (Figure 3g ). In addition, genes that are direct targets of IRF4 and upregulated in ASCs (Shaffer et al., 2008) were significantly enriched in the in vitro generated T-bet hi Be1 B DN cells relative to the Be2 B DN cells (Figure 3h ). Figure 4a ). In addition, both TLR7 and TLR9 were predicted as upstream regulators of the T-bet hi B DN Be1 cells (Figure 4a ). This was unexpected, given that we did not add exogenous TLR ligands to the co-cultures, however, endogenous TLR7 and TLR9 ligands are known to be released by dying cells in vitro (Sindhava et al., 2017) . Next, we addressed whether stimulation of B N cells with the IPA-predicted activators of the T-bet hi B DN transcriptional network was sufficient to induce the formation of the T-bet hi B DN pre-ASC population. We therefore stimulated HD B N cells with anti-Ig, cytokines (IFNg, IL-2, IL-21 and BAFF) and the TLR7/8 ligand, R848 ( Figure 4b ) and evaluated the B cells on day 6. We found that >95% of the B N cells activated with these defined stimuli resembled SLE patient T-bet hi DN2
cells (Jenks et al., 2018) as the in vitro activated cells were IgD neg CD27 neg T-bet hi IRF4 int , expressed the DN2 markers, CD11c and FcRL5, and were losing expression of CD21 and CXCR5 ( Figure 4g ). By contrast, when the cells were activated without IFNg, more than 80% of the cells were T-bet neg/lo ( Figure 4g ). While this wasn't particularly surprising, given that T-bet is IFNg-inducible (Stone et al., 2019) , the cells also failed to upregulate IRF4 (Figure 4g ), indicating that IFNg signals are obligate for the in vitro generation of the T-bet hi IRF4 int B DN pre-ASC like population.
Although HD B N cells activated with anti-Ig, cytokines and R848 developed in an IFNg-dependent fashion into T-bet hi IRF4 int B DN pre-ASC like cells (Figure 4g ), CD38 hi CD27 + ASCs did not accumulate in the cultures containing all stimuli ( Figure 4h ). This suggested that our defined cultures lacked a factor that was necessary for the differentiation of the T-bet hi pre-ASC-like cells into ASCs. Alternatively, it was possible that one or more of the stimuli present in the cultures either blocked differentiation or needed to be provided transiently during a discrete temporal window. Since anti-Ig was not added in our original in vitro Th1 and B N co-cultures, we first examined whether BCR signaling was blocking ASC development. We therefore stimulated B N cells for 6 days with the complete activation cocktail (+,+) or removed the anti-Ig from the activation cocktail for the first three days (-,+), last three days (+,-), or throughout the entire culture period (-,-) ( Figure 4i ). Consistent with our prior results, few ASCs were recovered when anti-Ig was included throughout the culture period ( Figure 4j) . Similarly, excluding anti-Ig from the culture for all 6 days or for the first 3 days also resulted in poor ASC recovery ( Figure 4j ). However, when anti-Ig was present only during the first 3 days of culture ASCs accumulated in the cultures ( Figure 4j ). These data therefore argued that early but transient BCR signals were important for the development and recovery of ASCs from cytokine and R848 stimulated B N cells. Next, we asked whether IFNg signals were required for the development of ASCs in the culture. We therefore activated B N cells with the cytokine cocktail and R848 for 6 days, including 3 days in the presence of anti-Ig and 3 days without anti-Ig. In individual cultures we excluded specific cytokines or R848 for all 6 days ( Figure 4k ). In agreement with our earlier experiment, ASCs were recovered ( Figure 4l ) when B cells were transiently activated with anti-Ig in the continuous presence of R848 and the complete cytokine cocktail. Although elimination of BAFF or IL-2 from the cultures decreased the number of ASCs recovered from the cultures (Figure 4l ), neither cytokine was obligate for ASC development. By contrast, and consistent with prior reports showing that ASC development from B N cells requires IL-21 (Ettinger et al., 2008; Tangye, 2015) , no ASCs were detected in the cultures lacking IL-21 ( Figure 4l) . Likewise, ASC recovery in cultures lacking R848 or IFNg was also at background levels ( Figure 4l) . Collectively, the data indicated that formation of the T-bet hi IR- Cartoon (i) depicting activation of HD B N cells for 3 days with R848, cytokines (IFNg, IL-2, IL-21, BAFF) ±anti-Ig (Step 1). Cells were then washed and recultured for an additional 3 days with the same stimuli ± anti-Ig (
Step 2). Enumeration of CD38 hi CD27 + ASCs (j) on day 6 in cultures that were not exposed to anti-Ig during Steps 1 and 2 (-,-); were exposed to anti-Ig throughout Steps 1 and 2 (+,+); were exposed to anti-Ig only in
Step 1 (+,-); or were exposed to anti-Ig only in
Step 2 (-,+). would be more critical later in the culture period (Days 4-6, differentiation phase). To test this hypothesis, we activated CTV-labeled B N cells for 3 days in the presence of anti-Ig and 3 days without anti-Ig -while adding the various stimuli minus one during the priming phase (+,-), during the differentiation phase (-,+) or throughout (+,+) the culture period ( Figure 5a ). We then measured proliferation, cell recovery and the frequency and number of ASCs present in cultures on day 6 (see Next, we analyzed when TLR7/8 signals were necessary for ASC development. When R848 was only added during the first 3 days, ASCs could not be detected in the cultures, whether measured as the frequency (Figure 5f ) or number (Figure 5g ) of ASCs. This was due, at least in part, to the fact that proliferation was severely stunted (Figure 5h ), resulting in greatly reduced cell recovery (Figure 5i ) in the day 6 cultures. When R848 was only added to the cultures between days 3-6, we observed no impact on pre-ASC formation ( Figure 5-figure supplement 1d) or the frequency of ASCs in the day 6 cultures (Figure 5f ). However, the number of cells recovered on day 6 was significantly reduced (Figure 5i) , which affected the number of ASCs recovered in the cultures (Figure 5g ). Despite the poor recovery of cells in the cultures that received TLR7/8 stimulation only between days 3-6, proliferation of the cells was not impacted (Figure 5h ). These data therefore indicated that R848 played both early and late roles in the development of ASCs, with early TLR7/8 signals appearing to promote B cell survival and late TLR7/8 signals promoting proliferation.
Finally, we assessed when IL-21 signals were required for ASC development. When IL-21 was only included for the first 3 days of the culture, pre-ASCs formed normally ( (Figure 5k ) of ASCs recovered from the cultures that were exposed to IL-21 between days 3-6 only were very similar to cells that were stimulated all 6 days in the presence of IL-21. Therefore, late IL-21 signals were sufficient to drive ASC formation. Thus, while inclusion of IFNg, TLR7/8 ligand and IL-21 throughout the entire culture period promoted optimal ASC recovery, IFNg and BCR signals were required during the priming phase, IL-21 was necessary during the later expansion and differentiation phase and R848 was important throughout the culture period (Figure 5n ). (Figure 5) , the B cells remained largely undivided when R848 was completely excluded from the cultures (Figure 6a) . By contrast, when high dose R848 was included in the cultures, the cells proliferated regardless of whether IFNg was included in the cultures for the first 3 days (Figure 6b ). However, when we activated B N cells with a 100-fold lower dose of TLR7/8 ligand, proliferation was only seen in the cultures that contained IFNg (Figure 6c) . Moreover, we observed that the frequency of ASCs in the cultures that were activated with low dose TLR ligand in the presence of IFNg was approximately 10-fold higher than that observed for the cultures that lacked IFNg (Figure 6d ). Similar results were seen when we cross-titrated the IFNg and R848 in the cultures (Figure 6-figure supplement 1) . Thus, exposure of B N cells to IFNg during the initial priming phase allowed these cells to differentiate even in the face of sub-optimal stimulation with R848. Next, we asked whether the IFNg priming signals enhanced the early response of B cells to cytokines. We first assessed cooperation between IFNg and IL-2 as IL-2, while not obligate for ASC development, did significantly enhance ASC recovery in our in vitro cultures (Figure 4) . We activated HD B N cells for 3 days with anti-Ig +R848 (Be.0 conditions), anti-Ig +R848+IL-2 (Be.IL2 conditions), anti-Ig +R848+IFNg (Be.IFNg conditions) or with anti-Ig +R848+IL-2+IFNg (Be.g2 conditions). We then washed and stimulated the cells for an additional 3 days with R848 +IL-21 (Figure 6e ) and evaluated cell recovery and ASC formation (see Figure 6 -figure supplement 2 for representative flow cytometry plots). As expected, we recovered very few viable cells (Figure 6f-g ) and no ASCs (Figure 6h-i) from the Be.0 cells on day 6. B cell proliferation ( Figure 6f ) and recovery of total cells ( Figure 6g ) and ASCs ( Figure 6i ) were also very low in the Be.IL2 cultures. Consistent with our earlier experiment ( Figure 5 ), ASCs were easily detected in the Be.IFNg cultures (Figure 6h-i) . However, when B cells were exposed to both IL-2 and IFNg during the early priming phase, the number of ASCs recovered on day 6 (Figure 6i ) was significantly more than seen in the Be.IFNg or Be.IL2 cultures. This was due to an increase in the number of cells recovered (Figure 6g) and to an increase in the frequency of ASCs (Figure 6h ) in the cultures. Thus, early IFNg and IL-2 signals cooperate to induce formation and recovery of ASCs.
Finally, since IL-21 signaling was obligate for ASC differentiation in our in vitro cultures, we hypothesized that early IFNg signals might program the B cells to respond to IL-21. To test this hypothesis, we measured phosphorylation of the IL-21R associated TF, STAT3, before and after IL-21 stimulation in day 3 Be.0, Be.IL2, Be.IFNg and Be.g2 cells. Day 3 basal levels of phospho-STAT3 were similar and low in the Be.0, Be.IL2 and Be.IFNg cells and modestly higher in the Be.g2 cells (Figure 6j , see Figure 6 -figure supplement 3 for flow cytometry plots). However, following a 20 min exposure to IL-21, phospho-STAT3 levels were increased significantly in the B cells that were exposed to IFNg during the priming phase (Figure 6k (Figure 7a -b, see Figure 7 -figure supplement 1 for representative flow plots) and the T-bet hi pre-ASC like population was easily detected in the IFNg-containing cultures. As expected, distinct sets of DAR were found in all 4 groups of activated B cells (Figure 7c) , however the largest number of chromatin accessible regions was seen in the day 3 Be.g2 cells (Figure 7c) . Moreover, the chromatin accessibility pattern in the Be.g2 cells appeared to reflect cooperation or synergy between the IFNg and IL-2 signals ( Figure 7c ). Examination of chromatin accessibility within 100 bp surrounding consensus TF binding motifs revealed significant (see Supplementary file 4 for statistical analyses) enrichment in accessibility near T-bet binding sites in the B cells that were exposed to IFNg (Figure 7d) . Similarly, accessibility around STAT5 binding motifs was enriched in IL-2 exposed B cells ( Figure 7e) . However, the Be.g2 cells exhibited the greatest enrichment in chromatin accessibility surrounding both T-bet and STAT5 binding sites (Figure 7d-e) , suggesting that IFNg and IL-2 cooperate to remodel the epigenome. Consistent with this, binding motifs for NF-kB p65 and REL, TFs activated by anti-Ig and TLR7/8 stimulation (Kaileh and Sen, 2012) , were most accessible in the Be.g2 cells compared to all other groups (Figure 7f-g ). Moreover, chromatin accessibility surrounding the HOMER-defined IRF4 and BLIMP1 binding motifs (Heinz et al., 2010) was also highly enriched in the Be.g2 cells (Figure 7h-i) . These data therefore suggested that these key ASC initiating TFs were already exerting epigenetic changes to the genome of the Be.g2 cells, even before these cells were exposed to IL-21. Consistent with this finding, when we examined the PRDM1 (BLIMP1) locus, we identified 4 DAR that were each more accessible in the Be.g2 cells relative to the other cells (Figure 7j ). Although none of these DAR contained a T-bet binding motif, each DAR directly aligned with peaks previously identified in a published T-bet ChIP-seq analysis of GM12878 cells (ENCODE Project Consortium, 2012), suggesting that T-bet could be associated with TF complexes that bind to these regulatory regions. Moreover, 3 of the 4 PRDM1-associated DAR were also seen in T-bet hi DN2 cells purified from SLE patients (Figure 7j ), indicating that these DAR were present in the pre-ASC population found in SLE patients. Finally, given our data showing that IFNg and IL-2 potentiated signaling through the IL-21R, we examined the 2 DAR assigned to the IL21R locus of the day 3 cells (Figure 7k) . One of the DAR contained two putative T-bet binding motifs and was directly aligned with a T-bet ChIP-seq peak from GM12878 cells (ENCODE Project Consortium, 2012) (Figure 7k ). This DAR was only observed in the cells that were exposed to IFNg and was most enriched in the Be.g2 population. Interestingly, we identified the same DAR in the SLE patient T-bet hi DN2 cells (Figure 7k) , which are reported to be highly responsive to IL-21 (Jenks et al., 2018) . To address whether these early IFNg-dependent epigenetic changes in the IL21R were associated with altered expression of IL-21R, we measured IL-21R expression in the day 3 and day 6 stimulated cells. Although day 3 B cells from Be.IFNg and Be.g2 cultures expressed slightly higher levels of IL-21R compared to B cells from Be.0 and Be.IL2 cultures (Figure 7l) , IL-21R expression were comparable between all groups at this timepoint. By day 6 however, IL-21R expression levels were 5.5-6-fold higher in the B cells that were cultured in the presence of IFNg during the first 3 days (Figure 7m) . Taken together, the data suggested that early IFNg signals synergize with BCR, TLR and IL-2 signals to induce global changes in chromatin accessibility and promote increased TF binding at T-bet, NF-kB, STAT5, BLIMP1 and IRF4 binding sites as well as chromatin remodeling at the PRDM1 and IL21R loci. 
SLE patient T-bet hi DN2 cells differentiate into ASCs without a further requirement for BCR stimulation
Previous data from our group (Jenks et al., 2018) showed that the T-bet hi DN2 cells from SLE patients were transcriptionally distinct from conventional memory cells and, like B N cells (Tangye, 2015), require IL-21 signals to differentiate. Since our in vitro culture system accurately predicted that the T-bet hi DN2 cell differentiation would be IL-21 dependent, we hypothesized that the in vitro culture data could be used to make additional testable predictions about the molecular properties of the T-bet hi DN2 cells found in SLE patients. To evaluate this possibility, we first tested the prediction that IFNg-dependent ASC formation from the B N cells isolated from SLE patients would require transient BCR stimulation. We therefore purified T-bet lo B N cells (see (Figure 8e) , while B N cells failed to differentiate (Figure 8e ). Consistent with our predictions, ASCs were easily identified in the day 2.5 cultures containing T-bet hi DN2 cells (Figure 8e) . Indeed, ASC recovery was at least 50-fold higher in T-bet hi DN2 cell cultures compared to the B N cultures and only 2-3 times less than that seen with the memory B cell populations (Figure 8e ). These data therefore suggested that the expanded population of T-bet hi DN2 cells present in some SLE patients likely represent a population of IFNg, TLR ligand and antigen programmed primary effectors that can rapidly differentiate in a BCR-signaling independent manner into ASCs following IL-21 exposure. The importance of IFNg in driving human ASC commitment and differentiation in the context of autoimmune disease is discussed.
Discussion
Here we show that IFNg promotes the in vitro formation of a T-bet hi IRF4 int IgD neg CD27 neg (B DN ) population that is similar to the T-bet expressing CD11c hi CXCR5 neg B DN (referred to as DN2 cells) subset found in SLE patients (Jenks et al., 2018) and the CD11c hi Age-Associated B cells (ABCs) that accumulate in aged and autoimmune mice and humans (Domeier et al., 2016; Jackson et al., 2016; Lee et al., 2012) and recent studies from our group demonstrating a role for B cell expression of the IFNgR and the IFNg-inducible transcription factor T-bet in ASC development (Stone et al., 2019) , the role for IFNg and STAT1 signaling in human B cell differentiation is less clear. In fact, prior data showing that IFNg has only very modest effects on activation and differentiation of human B cells (Nakagawa et al., 1985; Splawski et al., 1989; Rousset et al., 1991) and that patients deficient in the IFN-activated transcription factor STAT1 produce Abs in response to some vaccines (Chapgier et al., 2009; Chapgier et al., 2006) (Bernabei et al., 2001; Sammicheli et al., 2011) . However, we find that IFNg synergizes with TLR7/8 ligand to promote multiple rounds of B cell proliferation -an important prerequisite of human ASC differentiation (Tangye et al., 2003) . Although in vitro experiments using human B cells show that IFNg can synergize with TLR7 and CD40 signals to promote upregulation of Bcl6 and the acquisition of a germinal center-like phenotype (Jackson et al., 2016) , our data extend these studies to show that IFNg and TLR7/8 signals also cooperate to promote human B cell differentiation. These results are analogous to studies showing that IFNa-directed signals can enhance TLR7-mediated human B cell differentiation (Jego et al., 2003; Bekeredjian-Ding et al., 2005) . Given the considerable overlap between genes regulated by IFNa and IFNg (Pollard et al., 2013) , it is possible that IFNa and IFNg may augment TLR7 signaling in human B cells by similar mechanisms. Our in vitro data suggest multiple ways in which early IFNg priming signals promote subsequent ASC differentiation and recovery. First, we show that IFNg cooperates with IL-2, BCR, TLR7/8 ligand to globally alter the epigenetic landscape of the activated B cells and to specifically increase chromatin accessibility surrounding NF-kB, STAT5 and T-bet binding sites. While it is not particularly surprising that IFNg signaling induces increased T-bet expression and alterations in chromatin accessibility around T-bet binding sites (see for example Iwata et al., 2017) , the finding that chromatin accessibility surrounding NF-kB and STAT5 binding motifs is also regulated by IFNg suggests that IFNg must augment TLR7/8 and IL-2-dependent signaling. This is consistent with our in vitro data showing synergistic effects on ASC recovery when IFNg is combined with IL-2 or R848. Second, we show that IFNg promotes commitment to the ASC lineage by inducing expression of IRF4 and modifying chromatin accessibility surrounding IRF4-binding sites within regulatory regions in the genome of the activated B N cells. Third, we find that IFNg signals promote chromatin accessibility within the PRDM1 (BLIMP1) locus and initiate chromatin remodeling around BLIMP1-binding sites within the genome of the activated B N cells. Finally, we demonstrate that IFNg signals alter chromatin accessibility within the IL21R locus of the activated B N cells and that this change in accessibility is associated with IFNg-dependent, increased expression of the IL-21R by the activated B N cells and with increased responsiveness of these cells to IL-21, as measured by phosphorylation of STAT3. Collectively, these data suggest that IFNg signals, when combined with BCR, TLR and IL-2R signals, poise human B N cells to differentiate in response to IL-21.
One key finding from this study is that IFNg-augmented ASC formation and recovery is highly reliant on TLR7/8 activation by its RNA and RNA/protein ligands, which are derived from viral pathogens and dead and dying cells (Avalos et al., 2010) . Signaling through TLR7 is known to be important in SLE as prior studies reveal that SNPs in the human TLR7 locus (Lee et al., 2016 ) and overexpression of TLR7 in mice (Pisitkun et al., 2006) are associated with increased SLE susceptibility while deletion of TLR7 protects mice from the development of SLE (Christensen et al., 2006) . Our data show that deletion of the IFNg-inducible transcription factor T-bet in B lineage cells prevents autoAb responses in a mouse model (Pisitkun et al., 2006 ) of TLR7-dependent SLE. Moreover, our data demonstrates that B cell intrinsic IFNg signaling induces a TLR7/8 hyperresponsive state in human B cells. This finding does not appear to be due to IFNg-dependent changes in the expression of TLR7 by the B cells (data not shown). Rather, we find that IFNg-exposed B N cells can respond and differentiate into ASCs when exposed to 100-fold lower concentration of TLR7/8 ligands than normally used to activate B cells. Given that we observed that even low levels of IFNg are sufficient to synergize with suboptimal concentrations of TLR7/8 ligands, we predict that B cells from autoimmune patients with detectable systemic levels IFNg will be highly sensitive to the presence of endogenous and exogenously derived TLR7 ligands.
Our data predict that TLR7-driven ASC responses are likely to be further enhanced in individuals who have increased levels of circulating IFNg. Consistent with this, we show that SLE patients who have higher systemic levels of IFNg also have more T-bet hi DN2 cells and higher autoAb titers. We and others Jenks et al., 2018 ) also report that the size of the T-bet hi DN2 population correlates with disease activity, particularly in African-American SLE patients. However, it is important to note that T-bet hi DN2 cells are unlikely to represent a purely 'pathogenic' population as we also find an inducible population of vaccine-specific T-bet hi CD27 neg DN2 cells in healthy individuals who were immunized with inactivated influenza virus (data not shown). Similarly, others report (Lau et al., 2017; Knox et al., 2017 ) a T-bet expressing CD27 + CD21 lo switched memory subset with pre-ASC attributes, which is induced following vaccination or infection. Thus, we speculate that the T-bet hi B cells, which are found in HD and autoimmune patients in the settings of acute and chronic inflammation driven by vaccination, infection, autoimmunity and aging, are formed in an IFNg-dependent manner and likely represent a pool of primary and secondary pre-ASCs as well as effector memory B cells that are epigenetically poised to differentiate. The IFNg-induced T-bet hi IRF4 int pre-ASC population that we characterized in our in vitro studies is similar to the T-bet hi DN2 subset that is expanded in SLE patients. Since the expansion of the T-bet hi DN2 cells in SLE patients correlates with systemic levels of IFNg and IFNg-induced cytokines, we postulate that the DN2 cells likely arise in an IFNg-dependent fashion in these patients. In support of this possibility, we demonstrate that the IFNg-directed changes in chromatin accessibility within the IL21R and PRDM1 loci seen in the in vitro generated T-bet hi IRF4 int pre-ASCs are also found in T-bet hi DN2 cells isolated from SLE patients. Moreover, we show that the molecular properties of the SLE DN2 subset and the in vitro generated IFNg-dependent T-bet hi B DN cells are similar and unique when compared to conventional memory B cells or B N cells. For example, as discussed above, IFNg primes the T-bet hi B DN cells to respond to subthreshold concentrations of R848. Similarly, SLE DN2 cells make augmented responses to TLR7/8-stimulation compared to other B cell subsets (Jenks et al., 2018) . We also show that SLE patient DN2 pre-ASCs and the in vitro generated T-bet hi B DN subset can differentiate without a need for additional BCR stimulation. This is similar to memory B cells but unlike what we find for B N cells. However, like B N cells (Deenick et al., 2013) , both the SLE DN2 subset Jenks et al., 2018) and the in vitro generated T-bet hi B DN subset require IL-21 to differentiate into ASCs. Thus, given the many shared phenotypic, molecular and functional properties of the in vitro generated T-bet hi B DN subset and the T-bet hi DN2 cells found in SLE patients, we think that the in vitro pre-ASC cultures described here could be used to better understand the development, maintenance and functional attributes of the T-bet hi DN2 cells that are expanded and associated with more severe disease in SLE patients.
In summary, we demonstrate that IFNg is critical for the in vitro formation of a T-bet hi IRF4 int pre-ASC population that is remarkably similar to the T-bet hi DN2 cells that accumulate in SLE patients who present with high autoAb titers, elevated disease activity and increased systemic levels of IFNg. We show that IFNg signals, particularly when combined with IL-2 and TLR7/8 + BCR ligands, initiate epigenetic reprogramming of human B cells -changes which poise the activated B N cells to respond to IL-21 and fully commit to the ASC lineage. Based on these results, we argue that blocking IFNg signaling in SLE patients should curtail development of T-bet hi DN2 pre-ASCs from primary B N cells, which would result in decreased autoAb production and reduced disease activity. However, results from a phase I trial examining IFNg blockade in SLE patients did not reveal a therapeutic benefit (Boedigheimer et al., 2017) . Interestingly, no African Americans SLE patients with nephritis were included in the study (Boedigheimer et al., 2017) . Given the data showing that T-bet hi DN2 cells are most expanded in African American patients with severe disease Jenks et al., 2018) and our data presented here showing that the DN2 cells likely develop in response to IFNg, we propose that future studies evaluating the efficacy of IFNg blockade in SLE patients should focus specifically on the subset of patients who present with elevated IFNg levels and significant expansion of the IFNg-inducible T-bet expressing DN2 pre-ASC population.
Materials and methods
Key resources Continued on next page À80˚C. Human PBMCs and tonsil mononuclear cells were either used immediately or were cryopreserved at À150˚C.
Human lymphocyte purification
Naïve CD4 + T cells and CD19 + B cells were isolated from human PBMCs or tonsils using EasySep enrichment kits (StemCell). B N cells were then positively selected using anti-IgD microbeads (Miltenyi). B cell subsets were sort-purified from PBMCs and tonsils as described in text.
Generation of Th1 and Th2 cells
Polarized CD4 + effector T cells were generated by activating purified HD naïve CD4 T cells with plate-bound anti-CD3 (UCHT1) and anti-CD28 (CD28.2) (both 5 mg/ml, Biolegend) in the presence of IL-2 (50 U/ml), IL-12 (1 ng/ml) and anti-IL4 (10 mg/ml) (Th1 conditions) or IL-2 (50 U/ml), IL-4 (20 ng/ ml), anti-IL12 (10 mg/ml) and anti-IFNg (10 mg/ml) (Th2 conditions). Cells were transferred into fresh media on day 3 and IL-2 was added, as needed. Cells were re-activated every 7 days using the same cultures conditions for 3 rounds of polarization. All cytokines and Abs except IL-2 (Peprotech) were purchased from R and D and T cell polarizing media contained Iscove's DMEM supplemented with penicillin (200 mg/ml), streptomycin (200 mg/ml), gentamicin (40 mg/ml), 10% FBS and 5% human serum blood type AB.
T/B co-cultures
Purified B cell subsets from HD or SLE patients were co-cultured in B cell media in the presence of IL-2 (50 U/ml)±IL-21 (10 ng/ml) with allogeneic in vitro generated Th1 or Th2 effectors (0.6 Â 10 6 cells/ml, ratio 5B:1T) for 5-6 days, as indicated. B cell media contained Iscove's DMEM supplemented with penicillin (200 mg/ml), streptomycin (200 mg/ml), gentamicin (40 mg/ml), 10% FBS, and insulin (5 mg/ml; Santa Cruz Biotechnology).
B cell activation with defined stimuli
Purified B cell subsets isolated from the tonsil or blood of HD or SLE patients were cultured (1 Â 10 6 cells/ml) for 3 days with 5 mg/ml anti-Ig (Jackson ImmunoResearch), 5 mg/ml R848 (InvivoGen), 50 U/ ml IL-2, 10 ng/ml BAFF, 10 ng/ml IL-21 (Peprotech) and 20 ng/ml IFNg (R and D) (Step 1). Cells were either directly analyzed or washed and recultured (2 Â 10 5 cells/ml) for an additional 3 days with the same stimuli (
Step 2). The number of ASCs and total cells recovered in cultures on day 6 were determined and then normalized based on cell input. In some experiments, anti-Ig, R848, IL-21, IL-2, IFNg or BAFF were omitted from the cultures during Step 1, or Step 2 or both steps. In other experiments, the concentration of R848 in Step 1 and Step 2 and/or the concentration of IFNg in Step1 was varied, as indicated in the text. In some experiments, B cell subsets isolated from blood of SLE patients and HD were stimulated for 2.5-6 days with R848 and IL-21, IL-2, BAFF and IFNg.
STAT3 phosphorylation assays
HD B N cells were cultured with 5 mg/ml anti-Ig and 5 mg/ml R848 alone (Be.0) or in combination with IFNg (Be.IFNg), IL2 (Be.IL2), or IL2 plus IFNg (Be.g2). On day 3 cells were washed and restimulated with medium alone or with IL-21 (10 ng/ml) for 20 min at 37˚C. The cells were fixed and permeabilized with BD Transcription Factor Phospho Buffer Set and intracellular staining with anti phospho-STAT3 was performed.
In vitro B cell proliferation
Purified B cell subsets (1À5 Â 10 6 cells/ml) were stained for 10 min at 37˚C with PBS diluted CellTrace Violet (Molecular Probes, Thermofisher). The cells were washed and either used in T effector co-culture experiments or were cultured in the presence of defined stimuli.
In vitro ASC differentiation B N cells were co-cultured with in vitro generated Th1 or Th2 cells plus IL-2 and IL-21. On day 6 of the co-culture B DN cells from both cultures were sort-purified and then cultured in 0.22mM-filtered conditioned media (media collected from the original T/B co-cultures). ASCs were enumerated after 18 hr by flow cytometry.
Cytokine measurements
Th1 and Th2 cells were restimulated with platebound anti-CD3 and anti-CD28 (both 5 mg/ml). Cytokine levels in restimulated T cell cultures and SLE patient plasma samples was measured using Milliplex MAG Human Cytokine/Chemokine Immunoassays (Millipore).
Elispot
Serial diluted B cells were transferred directly to anti-IgG (Jackson ImmunoResearch) coated ELI-SPOT plates (Millipore) for 6 hr. Bound Ab was detected with alkaline phosphatase-conjugated antihuman IgG (Jackson ImmunoResearch) followed by development with alkaline phosphatase substrate (Moss, Inc). ELISPOTs were visualized using a CTL ELISPOT reader. The number of spots detected per well (following correction for non-specific background) was calculated.
Anti-SMITH ELISAs
Anti-Smith IgG autoantibodies in plasma from SLE patients and healthy donors were detected using the enzymatic immunoassay kit (Alpha Diagnostic) according to the manufacturer protocol.
Flow cytometry
Single cell suspensions were blocked with 10 mg/ml FcR blocking mAb 2.4G2 (mouse cells) or with 2% human serum or human FcR blocking reagent (Miltenyi) (human cells) and then stained with fluorochrome-conjugated Abs. 7AAD or LIVE/DEAD Fixable Dead Cell Stain Kits (Molecular Probes/ ThermoFisher) were used to identify live cells. For intracellular staining, cells were stained with Abs specific for cell surface markers, fixed with formalin solution (neutral buffered, 10%; Sigma) and permeabilized with 0.1% IGEPAL (Sigma) in the presence of Abs. Alternatively, the transcription factor and phospho-transcription factor staining buffers (eBioscience) were used. Stained cells were analyzed using a FACSCanto II (BD Bioscience). Cells were sort-purified with a FACSAria (BD Biosciences) located in the UAB Comprehensive Flow Cytometry Core. Analysis was performed using FlowJo v9.9.3 and FlowJo v10.2.
RNA-seq library preparation and analysis
RNA samples were isolated from TRIzol (FisherThermo) treated sort-purified day 6 Be1 and Be2 IgD neg CD27 neg B cells. 300 ng of total RNA from 3 biological replicates per B cell subset was used as input for the KAPA stranded mRNA-seq Kit with mRNA capture beads (KAPA Biosystems). Libraries were assessed for quality on a bioanalyzer, pooled, and sequenced using 50 bp paired-end chemistry on a HiSeq2500. Sequencing reads were mapped to the hg19 version of the human genome using TopHat with the default settings and the hg19 UCSC KnownGene table as a reference transcriptome. For each gene, the overlap of reads in exons was summarized using the GenomicRanges package in R/Bioconductor. Genes that contained two or more reads in at least 3 samples were deemed expressed (11598 of 23056) and used as input for edgeR to identify differentially expressed genes (DEGs). P-values were false-discovery rate (FDR) corrected using the BenjaminiHochberg method and genes with a FDR of <0.05 were considered significant. Expression data was normalized to reads per kilobase per million mapped reads (FPKM). Data processing and visualization scripts are available (Scharer, 2019a; Scharer, 2019b; Scharer, 2019c ; copies archived at https://github.com/elifesciences-publications/genomePlots, https://github.com/elifesciences-publications/heatmap, and https://github.com/elifesciences-publications/plotScaledBEDfeatures respectively). All RNA-seq data is available from the GEO database under the accession GSE95282. See also Supplementary file 1.
ATAC-seq preparation and analysis
ATAC-seq data generated from the SLE B cell subsets was previously reported (Jenks et al., 2018) . ATAC-seq analysis on in vitro generated B cell was performed on 10,000 Be.0, Be.IFNg, Be.IL2 or Be.g2 cells as previously described (Scharer et al., 2016) . Sorted cells were resuspended in 25 ml tagmentation reaction buffer (2.5 ml Tn5, 1x Tagment DNA Buffer, 0.2% Digitonin) and incubated for 1 hr at 37˚C. Cells were lysed with 25 ml 2x Lysis Buffer (300 mM NaCl, 100 mM EDTA, 0.6% SDS, 1.6 mg Proteinase-K) for 30 min at 40˚C, low molecular weight DNA was purified by size-selection with SPRI-beads (Agencourt), and then PCR amplified using Nextera primers with 2x HiFi Polymerase Master Mix (KAPA Biosystems). Amplified, low molecular weight DNA was isolated using a second SPRI-bead size selection. Libraries were sequenced using a 50 bp paired-end run at the NYU Genome Technology Center. Raw sequencing reads were mapped to the hg19 version of the human genome using Bowtie (Langmead et al., 2009 ) with the default settings. Duplicate reads were marked using the Picard Tools MarkDuplicates function (http://broadinstitute.github.io/picard/) and eliminated from downstream analyses. Enriched accessible peaks were identified using MACS2 (Zhang et al., 2008) with the default settings. Differentially accessible regions were identified using edgeR v3.18.1 (Robinson et al., 2010) and a generalized linear model. Read counts for all peaks were annotated for each sample from the bam file using the Genomic Ranges (Lawrence et al., 2013 ) R/Bioconductor package and normalized to reads per million (rpm) as previously described (Scharer et al., 2016) . Peaks with a greater than 2-fold change and FDR < 0.05 between comparisons were termed significant. Genomic and motif annotations were computed for ATAC-seq peaks using the HOMER (Heinz et al., 2010) annotatePeaks.pl script. The findMotifsGenome.pl function of HOMER v4.8.2 (42) was used to identify motifs enriched in DAR and the 'de novo' output was used for downstream analysis. To generate motif footprints, the motifs occurring in peaks were annotated with the HOMER v4.8.2 annotatePeaks.pl function (Heinz et al., 2010 ) using the options '-size given'. The read depth at the motif and surrounding sequence was computed using the GenomicRanges v1.22.4 (66) package and custom scripts in R/Bioconductor. All other analyses and data display were performed using R/Bioconductor with custom scripts (Scharer, 2019a; Scharer, 2019b; Scharer, 2019c) . ATAC-seq data has been deposited in the NCBI GEO database under accession number GSE119726. See also Supplementary files 3-5 for complete list of DAR and for analysis of TF motif enrichment in the ATAC-seq dataset.
GSEA
For gene set enrichment analysis samples were submitted to the GSEA program (http://software. broadinstitute.org/gsea/index.jsp). For the comparison of interest (i.e., B DN Be1 and B DN Be2 cells), all detected genes were ranked by multiplying the -log 10 of the P-value from edgeR by the sign of the fold change and used as input for the GSEA Preranked analysis. The custom gene set defining genes upregulated in SLE T-bet hi B DN relative to other B cell subsets were derived from Jenks et al.
(2018) and are listed in Supplementary file 2.
Ingenuity Pathway Analysis (IPA)
IPA upstream regulator analysis (Krämer et al., 2014, Qiagen, Redwood City CA) was performed using the log 2 fold-change in gene expression between genes that were significantly differentially expressed (FDR < 0.05) in B DN Be1 and B DN Be2 cells. Upstream regulators with an activation z-score of !2 or À2 were considered to be activated or inhibited in B DN Be1 cells. Overlap P-value (between the regulator's downstream target list and the DEG list was based on Fisher's exact test.
Statistical analysis
Comparisons between two groups were performed with the Student's t test for normally distributed variables and the Mann-Whitney test for non-normally distributed variables. The one-way ANOVA test was used to compare mean values of 3 or more groups and the Kruskal-Wallis nonparametric test was used to compare medians. Strength and direction of association between two variables measures was performed using the D'Agostino-Pearson normality test followed by Pearson's or Spearman's correlation test. Data were considered significant when p 0.05. Analysis of the data was done using the GradhPad Prism version 7.0a software (GraphPad). See Supplementary file 5 for all statistical comparisons.
Mice and bone marrow chimeras
All experimental animals were bred and maintained in the UAB animal facilities. All procedures involving animals were approved by the UAB Institutional Animal Care and Use Committee and were conducted in accordance with the principles outlined by the National Research Council. B6.SBYaa/J.B6;129S-Fcgr2b tm1Ttk /J (Yaa.Fcgr2b -/-) (Pisitkun et al., 2006 ) (obtained by permission from Dr.
Sylvia Bolland (NIH)) were intercrossed with B6.129S2-Ighm tm1Cgn /J (mMT) or B6.129S6-Tbx21 tm1Glm / J (Tbx21 -/-) mice (both strains obtained from Jackson Laboratory) to produce B cell deficient (Yaa.
Fcgr2b
-/-.mMT) or T-bet deficient (Yaa.Fcgr2b -/-.Tbx21 -/-) lupus-prone mice. To generate bone marrow chimeras, mMT recipient mice were irradiated with 950 Rads from a high-energy X-ray source, delivered in a split dose 4 hr apart. Recipients were reconstituted (10 7 total BM cells) with 80% Yaa. 
Mouse ANA detection and imaging
Antinuclear antibodies (ANA) were detected by an indirect immunofluorescence assay using HEp-2 cells. Fixed HEp-2-coated microscope slides (Kallestad, BioRad) were blocked, incubated with serum diluted 1:100 and stained with anti-IgG-FITC (Southern Biotech) (10 mg/ml). Slides were mounted with SlowFade Gold Antifade Mountant with DAPI (ThermoFisher) and imaged. Anti-nuclear staining was quantitated as the mean flourescence intensity (MFI) of IgG-FITC over DAPI-staining areas (nuclei) using NIS-Elements AR software (Nikon). Data are presented as log nuclear IgG MFI normalized by subtracting the MFI of negative control serum from B6 mice. ANA images were collected using a Nikon Eclipse Ti inverted microscope and recorded with a Clara interline CCD camera (Andor). The images were taken with a 20X (immunofluorescence) objective for 200-400X final magnification. Images were collected using NIS Elements software, scale bars were added and images were saved as high-resolution JPEGs. JPEG images were imported into Canvas Ver 12 software and were resized, cropped with the identical settings applied to all immunofluorescence images from the same experiment. Final images presented at 600-650 dpi (ANA).
Urinary Albumin to Creatinine Ratio (UACR)
Albumin concentrations in urine samples, collected from live or euthanized mice, were measured using the Mouse Albumin ELISA Quantitation Set (Bethyl Labs) according to manufacturer's protocol using a mouse reference serum as an albumin standard. To normalize for urine concentration, urinary creatinine was measured by liquid chromatography-mass spectrometry in the UAB/UCSD O'Brien Core Center for Acute Kidney Injury Research. The UACR was calculated as mg/ml albumin divided by mg/ml creatinine and is reported as mg albumin/mg creatinine. Data availability Sequencing data have been deposited in GEO under accession codes GSE95282 and GSE118984. All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files for sequencing analysis are included as Supplementary Files 1 and 2 (excel files).
The following datasets were generated: The following previously published datasets were used:
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